Management & Regulatory

Bora Pharmaceuticals Expands with Tanvex Stake and Key Acquisitions
Management & Regulatory Bora Pharmaceuticals Expands with Tanvex Stake and Key Acquisitions

Bora Pharmaceuticals' recent strategic maneuvers have significantly bolstered its presence in the Contract Development and Manufacturing Organization (CDMO) sector, showcasing its intent to become a top contender in the biomanufacturing industry. In a notable move, Bora has acquired a 30.5% stake

What Are Theravance Biopharma’s Prospects Amidst Mixed Signals?
Management & Regulatory What Are Theravance Biopharma’s Prospects Amidst Mixed Signals?

Theravance Biopharma Inc (NASDAQ: TBPH) has been navigating a complex landscape filled with mixed signals, affecting its market performance and generating varied sentiment among analysts and investors alike. This article delves into recent developments surrounding the company, including key

Enzo Biochem Settles for $4.5M Over 2023 Data Breach, Tightens Security
Management & Regulatory Enzo Biochem Settles for $4.5M Over 2023 Data Breach, Tightens Security

In a significant move reflecting the growing regulatory pressure on data security practices, Enzo Biochem has reached a settlement with the Attorneys General of Connecticut, New York, and New Jersey over allegations of inadequate security measures leading to a data breach earlier this year. The

Bora Pharmaceuticals Expands with Major Stake in Tanvex BioPharma
Management & Regulatory Bora Pharmaceuticals Expands with Major Stake in Tanvex BioPharma

Bora Pharmaceuticals continues its robust expansion by acquiring a significant operational stake in Tanvex BioPharma, a deal set to close in early 2025. This strategic acquisition positions Bora as the largest shareholder in Tanvex, granting the company access to a commercial-scale production

How Will Bora’s Stake in Tanvex Shape the Biotech Industry’s Future?
Management & Regulatory How Will Bora’s Stake in Tanvex Shape the Biotech Industry’s Future?

The acquisition of a 30.5% stake in Tanvex Biopharma by Bora Pharmaceuticals is a pivotal development in the biotech sector. As the largest single corporate shareholder in Tanvex, Bora aims to leverage this strategic partnership to enhance its competitive edge in the global biopharmaceutical

How Will Overturning Chevron Doctrine Affect Biopharma Industry?
Management & Regulatory How Will Overturning Chevron Doctrine Affect Biopharma Industry?

The recent decision by the Supreme Court to overturn the Chevron doctrine marks a significant shift in administrative law, with profound implications for the healthcare industry, particularly for federal regulators like the FDA (Food and Drug Administration) and the CMS (Centers for Medicare &

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later